Abstract Details

Title a-Interferon for Recurrent Surgery and Radiation Refractory High-Grade Meningioma: A Retrospective Case Series

Topic Neuro-oncology

Presentation(s) P01 - (-)

Poster/Presentation
Number 095

Objective

Background Limited literature is available regarding the treatment of recurrent surgery and radiation refractory meningioma and that available is primarily with respect to treatment of low grade (WHO Grade 1) meningioma.

Design/Methods 35 patients (28 women; 17 men: median age 63 years, range 36-86) with recurrent high-grade meningioma were treated with a-interferon (5,000 Units/m2) subcutaneously once every other day; one cycle operationally defined as 4 weeks of aIFN. Patients had progressed radiographically after prior therapy with surgery (35/35), radiotherapy (35/35: external beam radiotherapy 35/35; stereotactic radiotherapy 34/35) and hydroxyurea chemotherapy. One patient was treated with a somatostatin analog as well before initiating aIFN.

Results Patients received 1-13 cycles (median 3.0) of aIFN with moderate toxicity (100% all grades and 43% grade 3+). There were no radiographic responses, 54% of patients had stable disease and 47% manifested progressive disease at first evaluation. PFS was 17% at 6 months [95% CI 0.07-0.31] (median PFS 12 weeks [95% CI 8-20 weeks]; range 4-52 weeks). The majority of patients (60%) following progression on aIFN were subsequently treated on an alternative therapy.

Conclusions In this retrospective series, aIFN was moderately toxic however appeared to have modest activity in patients with recurrent high-grade meningiomas.

Authors/Disclosures
Marc Chamberlain, MD (Cascadian Therapeutics) PRESENTER	No disclosure on file
Christopher H. Gibbons, MD, FAAN (Beth Israel Deaconess Medical Center)	Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has or had stock in CND Life Sciences.Dr. Gibbons has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��